Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
AstraZeneca
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Tesaro, Inc.
Tesaro, Inc.
Mayo Clinic
Hoffmann-La Roche
M.D. Anderson Cancer Center
Tesaro, Inc.
Hoffmann-La Roche
M.D. Anderson Cancer Center
GOG Foundation
Gradalis, Inc.
Roswell Park Cancer Institute
Duke University
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Western Regional Medical Center
Ohio State University Comprehensive Cancer Center
Hoffmann-La Roche
Genentech, Inc.
University of Oklahoma
MedImmune LLC
Dana-Farber Cancer Institute
University of Pittsburgh
Hoffmann-La Roche
Massachusetts General Hospital
Memorial Sloan Kettering Cancer Center
NYU Langone Health
New Mexico Cancer Research Alliance
Benaroya Research Institute
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
Genentech, Inc.
Washington University School of Medicine
Dana-Farber Cancer Institute
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center